AJANTPHARMBSEAjanta Pharma LtdHighNeutral
Announced Thu, 18 Jun · 10:49 IST

Ajanta Pharma FY26 Annual Report: Revenue Rs 5,453 cr, PAT Rs 1,056 cr

Exceptional ItemResults View source PDF

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹3060.00
prior close
₹3067.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+0.1+0.3-0.1+0.4+4.2+4.2+6.4+4.3+11.9+10.0+13.3
Up moveDown movePending
AI summary

Ajanta Pharma's FY26 Annual Report shows revenue up 17% to Rs 5,453 cr, adjusted EBITDA up 18% to Rs 1,498 cr (27% margin), and PAT up 15% to Rs 1,056 cr. US Generics surged 49% to Rs 1,557 cr. India grew 14%, Africa 15%, Asia declined 1% on Middle East issues. EPS rose to Rs 85. Dividend payout Rs 350 cr. 47th AGM on July 16, 2026.

Likely market impact

Strong FY26 with revenue crossing Rs 5,000 cr and PAT Rs 1,000 cr. US Generics surged 49%. Rs 350 cr dividend. AGM on July 16.